Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 01, 2023, titled "Zydus receives final approval from the USFDA for Erythromycin Tablets USP, 250 mg and 500 mg".
Press Release Sep 01 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Erythromycin Tablets USP in two dosages. The tablets are used to treat various infections and will be manufactured in Ahmedabad, India. The press release highlights that the product had significant annual sales in the United States.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Aug 31 2023
- Press Release Aug 25 2023
- Press Release (Revised) Aug 24 2023
- Press Release Aug 24 2023
- Press Release Aug 17 2023
Later from Zydus Lifesciences
- Press Release Sep 13 2023
- Press Release Sep 15 2023
- Press Release Sep 19 2023
- Press Release Sep 20 2023
- Press Release Sep 29 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences